{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:39:52Z","timestamp":1789799992738,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s10067-014-2823-8","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T14:07:28Z","timestamp":1416578848000},"page":"715-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Adherence and persistence to urate-lowering therapies in the Irish setting"],"prefix":"10.1007","volume":"35","author":[{"given":"Bernie","family":"McGowan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kath","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Silke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,20]]},"reference":[{"key":"2823_CR1","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1001\/jama.289.21.2857","volume":"289","author":"KT Rott","year":"2003","unstructured":"Rott KT, Agudelo CA (2003) Gout. JAMA 289:2857\u20132860","journal-title":"JAMA"},{"issue":"3","key":"2823_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaska H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51(3):321\u2013325","journal-title":"Arthritis Rheum"},{"key":"2823_CR3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3199","volume":"12","author":"E Roddy","year":"2010","unstructured":"Roddy E, Doherty M (2010) Epidemiology of Gout. Arthritis Res Ther 12:223","journal-title":"Arthritis Res Ther"},{"key":"2823_CR4","unstructured":"Arthritis Ireland: http:\/\/www.arthritisireland.ie\/go\/information\/frequently_asked_questions . (Accessed: August 13th 2013)"},{"key":"2823_CR5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semarthrit.2008.01.011","volume":"38","author":"LR Harrold","year":"2009","unstructured":"Harrold LR, Andrade SE (2009) Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 38:396\u2013402","journal-title":"Semin Arthritis Rheum"},{"key":"2823_CR6","first-page":"44","volume":"30","author":"E Klerk de","year":"2003","unstructured":"de Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S (2003) Patients compliance in rheumatoid arthritis, polymyalgia rheumatic, and gout. J Rheumatol 30:44\u201354","journal-title":"J Rheumatol"},{"issue":"10","key":"2823_CR7","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liot\u00e9 F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Piment\u00e3o J, Punzi L, Roddy E, Uhlig T, Zimmermann-G\u00f2rska I (2006) EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 65(10):1312\u20131324","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2823_CR8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76(1):47\u201356","journal-title":"Am J Med"},{"issue":"2","key":"2823_CR9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63(2):412\u2013421","journal-title":"Arthritis Rheum"},{"key":"2823_CR10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1471-2474-13-174","volume":"13","author":"N Dalbeth","year":"2012","unstructured":"Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ (2012) Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskelet Disord 13:174","journal-title":"BMC Musculoskelet Disord"},{"key":"2823_CR11","unstructured":"HSE-Primary Care Reimbursement Service Statistical Analysis of Claims and Payments 2011. http:\/\/www.hse.ie\/eng\/staff\/PCRS\/PCRS_Publications\/pcrsclaimsandpayments2011.pdf Accessed September 22nd 2013"},{"key":"2823_CR12","unstructured":"WHO anatomical therapeutic chemical classification. Oslo: WHO, 2013. http:\/\/www.whocc.no\/atc_ddd_index\/ Accessed: May 10th 2013"},{"key":"2823_CR13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","volume":"15","author":"SE Andrade","year":"2006","unstructured":"Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automateddatabases. Pharmacoepidemiol Drug Saf 15:565\u2013574","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2823_CR14","first-page":"761","volume":"41","author":"KL Sloan","year":"2003","unstructured":"Sloan KL, Sales AE, Liu CF, Nichol P, Suzuki NT, Sharp ND (2003) Construction and characteristics of the RxRisk V: A VA adapted pharmacy based case \u2013mix instrument. Med Care 41(6):761\u2013774","journal-title":"Med Care"},{"key":"2823_CR15","author":"MP O'Shea","year":"2013","unstructured":"O'Shea MP, Teeling M, Bennett K (2013) An observational study examining the effect of co morbidity on the rates of persistence and adherence to newly initiated oral anti-hyperglycaemic agents. Pharmacoepidemiol Drug Saf. doi: 10.1002\/pds.3535","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2823_CR16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ncprheum0556","volume":"3","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M (2007) The changing epidemiology of gout. Nat Clin Pract Rheumatol 3:443\u2013449","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2823_CR17","first-page":"1582","volume":"31","author":"KL Wallace","year":"2004","unstructured":"Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31:1582\u20131587","journal-title":"J Rheumatol"},{"key":"2823_CR18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V","volume":"41","author":"RC Lawrence","year":"1998","unstructured":"Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778\u2013799","journal-title":"Arthritis Rheum"},{"key":"2823_CR19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","volume":"58","author":"CG Helmick","year":"2008","unstructured":"Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58:15\u201325","journal-title":"Arthritis Rheum"},{"key":"2823_CR20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","volume":"58","author":"RC Lawrence","year":"2008","unstructured":"Lawrence RC, Felson DT, Helmick CG et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58:26\u201335","journal-title":"Arthritis Rheum"},{"key":"2823_CR21","first-page":"2403","volume":"29","author":"E Arromdee","year":"2002","unstructured":"Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403\u20132406","journal-title":"J Rheumatol"},{"key":"2823_CR22","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/0895-4356(94)00244-K","volume":"48","author":"CM Harris","year":"1995","unstructured":"Harris CM, Lloyd DC, Lewis J (1995) The prevalence and prophylaxis of gout in England. J Clin Epidemiol 48:1153\u20131158","journal-title":"J Clin Epidemiol"},{"key":"2823_CR23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","volume":"64","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG (2005) Gout epidemiology: results from the UK general practice research database, 1990\u20131999. Ann Rheum Dis 64:267\u2013272","journal-title":"Ann Rheum Dis"},{"key":"2823_CR24","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","volume":"67","author":"L Annemans","year":"2008","unstructured":"Annemans L, Spaepen E, Gaskin M et al (2008) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005. Ann Rheum Dis 67:960\u2013966","journal-title":"Ann Rheum Dis"},{"key":"2823_CR25","first-page":"S435","volume":"11","author":"AJ Luk","year":"2005","unstructured":"Luk AJ, Simkin PA (2005) Epidemiology of hyperuricemia and gout. Am J Manag Care 11:S435\u2013S442","journal-title":"Am J Manag Care"},{"issue":"4","key":"2823_CR26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","volume":"28","author":"BA Briesacher","year":"2008","unstructured":"Briesacher BA, Andrade SE, Fouayzi H, Chan KA (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28(4):437\u2013443","journal-title":"Pharmacotherapy"},{"issue":"8","key":"2823_CR27","first-page":"1575","volume":"31","author":"AA Riedel","year":"2004","unstructured":"Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M (2004) Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 31(8):1575\u20131581","journal-title":"J Rheumatol"},{"issue":"2","key":"2823_CR28","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/ar2659","volume":"11","author":"LR Harrold","year":"2009","unstructured":"Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS (2009) Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 11(2):R46","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2823_CR29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/ard.2007.076182","volume":"67","author":"DH Solomon","year":"2008","unstructured":"Solomon DH, Avorn J, Levin R, Brookhart MA (2008) Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 67(5):609\u2013613","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2823_CR30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kes431","volume":"52","author":"G Zandman-Goddard","year":"2013","unstructured":"Zandman-Goddard G, Amital H, Shamrayevsky N, Raz R, Shalev V, Chodick G (2013) Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology (Oxford) 52(6):1126\u20131131","journal-title":"Rheumatology (Oxford)"},{"key":"2823_CR31","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1345\/aph.1C044","volume":"36","author":"SJ Shalansky","year":"2002","unstructured":"Shalansky SJ, Levy AR (2002) Effect of number of medications on cardiovascular therapy adherence. Ann Pharmacother 36:1532\u20131539","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2823_CR32","first-page":"71","volume":"14","author":"Y Rozenfeld","year":"2008","unstructured":"Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS (2008) Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 14(2):71\u201375","journal-title":"Am J Manag Care"},{"issue":"17","key":"2823_CR33","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/archinte.166.17.1836","volume":"166","author":"PM Ho","year":"2006","unstructured":"Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ (2006) Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 166(17):1836\u20131841","journal-title":"Arch Intern Med"},{"issue":"10","key":"2823_CR34","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.clinthera.2008.10.003","volume":"30","author":"C Cheong","year":"2008","unstructured":"Cheong C, Barner JC, Lawson KA, Johnsrud MT (2008) Patient adherence and reimbursement amount for anti diabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 30(10):1893\u20131907","journal-title":"Clin Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2823-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2823-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2823-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:57:38Z","timestamp":1559120258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2823-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,20]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["2823"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2823-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,20]]}}}